- cafead Dec 06, 2020 at 07:22: PM
via Syros $SYRS CEO Nancy Simonian had more than data to discuss during the virtual ASH sessions this weekend.
On top of a new cut of the data for their lead cancer drug, SY-1425, a trio of Bain execs has stepped in to set up a major new infusion of funds along with a new product acquisition aimed at beefing up the pipeline as they shoot for the proverbial “fully integrated” status of a commercial player.
article source
On top of a new cut of the data for their lead cancer drug, SY-1425, a trio of Bain execs has stepped in to set up a major new infusion of funds along with a new product acquisition aimed at beefing up the pipeline as they shoot for the proverbial “fully integrated” status of a commercial player.
article source